Your session is about to expire
← Back to Search
Vaccine
Homologous booster vaccine group for Multiple Sclerosis
Phase < 1
Waitlist Available
Led By Joseph B Guarnaccia, MD
Research Sponsored by Griffin Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-6 weeks
Awards & highlights
Study Summary
This trial is testing if a higher dose of vaccine will help people with MS who are on immune-suppressing therapies to develop antibodies to the COVID-19 virus.
Eligible Conditions
- Multiple Sclerosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4-6 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-6 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent who test positive for COVID-19 spike protein antibodies following booster
Secondary outcome measures
Comparison of COVID-19 spike protein antibodies based on booster received
Comparison of COVID-19 spike protein antibodies based on disease-modifying treatment
Correlation of COVID-19 spike protein antibodies with B and T cell levels and immunoglobulins
Trial Design
2Treatment groups
Active Control
Group I: Homologous booster vaccine groupActive Control1 Intervention
A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
Group II: Heterologous booster vaccine groupActive Control1 Intervention
A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
Find a Location
Who is running the clinical trial?
Yale-Griffin Prevention Research CenterOTHER
3 Previous Clinical Trials
258 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
58 Patients Enrolled for Multiple Sclerosis
Multiple Sclerosis Treatment CenterUNKNOWN
Griffin HospitalLead Sponsor
24 Previous Clinical Trials
1,528 Total Patients Enrolled
3 Trials studying Multiple Sclerosis
78 Patients Enrolled for Multiple Sclerosis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger